TAT and ischemia: Treatment with Tat-SH3GL2 significantly mitigated the reduction of PSD95, synaptophysin, and SNAP-25 protein levels in the hippocampus 1 and 4 days after ischemia, indicating that Tat-SH3GL2 prevents the reduction of synaptic plasticity in the hippocampal CA1 region after transient forebrain ischemia.